Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,307 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Oncology Care Clear all
Completed Phase 3 Interventional Results available

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

NCT04209114
View directory record Official record
Conditions
Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer
Interventions
Nivolumab, Radical cystectomy (RC), Bempegaldesleukin
Biological · Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 4, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

NCT07594015
View directory record Official record
Conditions
Recurrent Endometrial Cancer
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

NCT05553808
View directory record Official record
Conditions
Neoplasms
Interventions
Docetaxel, Feladilimab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Not applicable Interventional

Molecular Analysis for Precision Surgery in Thyroid Cancer Trial

NCT06235814
View directory record Official record
Conditions
Papillary Thyroid Cancer
Interventions
Molecular Analysis for Thyroid Resection
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

NCT04340258
View directory record Official record
Conditions
HNSCC
Interventions
Cesium-131, Pembrolizumab
Device · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
19 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT02167958
View directory record Official record
Conditions
Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
Drug · Radiation · Other
Lead sponsor
Rafic Farah, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 4, 2026, 11:12 AM EDT
Terminated Phase 3 Interventional Results available

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

NCT03839940
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Dexamethasone, Placebo, Questionnaire, Quality-of-Life Assessment, Everolimus
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
319
States / cities
Birmingham, Alabama • Kingman, Arizona • Fort Smith, Arkansas + 198 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Early Phase 1 Interventional

Utility of ICG in Benign Bone Tumors

NCT05075889
View directory record Official record
Conditions
Bone Tumor
Interventions
Indocyanine Green
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
12 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 4, 2026, 11:12 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

COMUNICAR: Community-Led Family-Centered Communication for Cancer Survivorship Care

NCT07606443
View directory record Official record
Conditions
Childhood Cancer
Interventions
Family-Centered Communication Intervention
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Active, not recruiting Phase 2 Interventional

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

NCT04028063
View directory record Official record
Conditions
Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
Interventions
Balstilimab, Zalifrelimab, Doxorubicin, Botensilimab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis

NCT05059678
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Best Practice, Educational Intervention, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Active, not recruiting Phase 3 Interventional

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738
View directory record Official record
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions
Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
47
States / cities
Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

End Diagnostic Overshadowing

NCT06608758
View directory record Official record
Conditions
Disabilities Multiple
Interventions
Electonic health record prompts with education, Standard of care
Behavioral · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
3 Years to 89 Years
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCT02352948
View directory record Official record
Conditions
Non - Small Cell Lung Cancer NSCLC
Interventions
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
33
States / cities
Chandler, Arizona • Anaheim, California • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 4, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

NCT05837455
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Not applicable Interventional Results available

Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation

NCT03244826
View directory record Official record
Conditions
Other Cancer
Interventions
Shared Care, Standard Care
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Stamford, Connecticut • Bangor, Maine • Brunswick, Maine + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 4, 2026, 11:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors

NCT05660408
View directory record Official record
Conditions
Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma
Interventions
pp65 RNA LP (DP1), pp65/tumor mRNA RNA-LP (DP2), Surgical Biopsy/Resection
Biological · Procedure
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 39 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Recruiting Not applicable Interventional

Feasibility of Transcranial Focused Ultrasound to Measure Brain Tumor

NCT05755399
View directory record Official record
Conditions
Cranial Neurosurgery
Interventions
Brain imaging using transcranial focused ultrasound (tFUS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

NCT04151667
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

NCT02509598
View directory record Official record
Conditions
Rhabdomyosarcoma, Melanoma
Interventions
Tc99m tilmanocept, Vital Blue Dye (optional), Lymph Node Mapping
Drug · Procedure
Lead sponsor
Cardinal Health 414, LLC
Industry
Eligibility
Up to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Orlando, Florida • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Not applicable Interventional

Emotions Immunology and Breast Cancer

NCT03609671
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, Emotions, Immunology
Interventions
Standard of Care + Experimental Individualized Therapy, Control: Standard of Care
Behavioral · Other
Lead sponsor
Luz A. Venta, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 4, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

NCT05240898
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
RO7623066, Olaparib, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Orange, California • New Haven, Connecticut • Detroit, Maine + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 4, 2026, 11:12 AM EDT
Suspended Phase 3 Interventional

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

NCT06671912
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
728
States / cities
Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 4, 2026, 11:12 AM EDT